J
Judo Bio
Innovative oligonucleotide medicines targeting kidney diseases through proprietary siRNA delivery technology
About Judo Bio
Judo Bio is at the forefront of developing oligonucleotide medicines specifically targeting the kidney, an organ traditionally challenging for genetic treatments. The company operates within the biotechnology sector, focusing on creating RNA-based therapies for both systemic and renal diseases. Judo Bio's unique STRIKE platform leverages a natural mechanism to deliver siRNA, a type of genetic material, directly to kidney cells. This approach allows for the silencing of disease-causing genes by targeting specific solute carrier proteins, which are crucial for kidney function. The business model revolves around the development and commercialization of these proprietary therapies, aiming to partner with pharmaceutical companies for distribution and further development. Revenue is generated through licensing agreements, collaborations, and potential future sales of approved therapies. Judo Bio primarily serves healthcare providers and pharmaceutical companies looking for advanced treatments for kidney-related conditions. The company is positioned in a niche market with significant growth potential due to the increasing demand for innovative genetic therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Cambridge, United States
- Employees
- 32
- Open positions
- None listed
- Dealroom signal
- 60.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Oct 2024 | $75M | $300M | Atlas Venture · The Chernin Group · Alexandria Venture Investments · Euclidean Capital | ↗ |
| SEEDOther financing | Apr 2024 | $25M | $100M | The Column Group | ↗ |
Growth signals
Latest recorded traffic for Judo Bio is 2.5K monthly website visits, down 10.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
The Column Group
Series A7 investors entered at this stage
Atlas Venture
The Chernin Group
Droia Oncology Ventures
Alexandria Venture Investments- ECEuclidean Capital
Digitalis Ventures
YK Bioventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Judo Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Judo Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.